TechFlow news, November 6 — According to Globenewswire, Datavault AI Inc. (Nasdaq: DVLT), a publicly traded U.S. company, announced it has entered into a $10 million exclusive global licensing agreement with Scilex Holding Company (Nasdaq: SCLX).
Under the agreement, Scilex will obtain exclusive global rights from Datavault AI to utilize its artificial intelligence technology for creating and operating a biotechnology trading platform within the biotechnology and biopharmaceutical industries. The platform will enable secure tokenization, trading, and monetization of biotech assets such as genomics and DNA data, diagnostic and therapeutic products, genetic information, and drug data.
Add to Favorites
Share to Social Media
